Home » Topics » BioWorld Science

BioWorld Science
RSS

Millennium Pharmaceuticals initiates first-in-human trial of TAK-164

May 3, 2018

First-in-human study of hepatitis B DNA vaccine JNJ-64300535

May 3, 2018

Enrollment ongoing in phase III trial of enfortumab vedotin for urothelial cancer

May 3, 2018

EMA approves Alpivab for the treatment of influenza

May 3, 2018

YW-1128, a WNT pathway inhibitor, shows promising in vivo results for metabolic disorders

May 3, 2018

Janssen to acquire Benevir Biopharm

May 3, 2018

Merck KGaA and SFJ partner on abituzumab in metastatic colorectal cancer

May 3, 2018

SignalRx discovers selective BRD4-BD1 inhibitor

May 3, 2018

Crysvita launched in U.S. for X-linked hypophosphatemia

May 3, 2018

FDA grants fast track designation to ACE-083 for facioscapulohumeral muscular dystrophy

May 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads
BioWorld
Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and...